uniQure (QURE) – Management Comments
-
uniQure (QURE) Reports Positive Recommendation from DSB of Phase I/II Clinical Trial of AMT-130 for Treatment of Huntington’s Disease
-
uniQure (QURE) Reports 2-Yr Follow-Up Data from Phase IIb Study of Etranacogene Dezaparvovec & Long-Term Follow-Up Data for AMT-060
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to QURE Stock Lookup